NASDAQ:FOLD - Amicus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.42
  • Forecasted Upside: 105.61 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$9.93
▼ -0.27 (-2.65%)
1 month | 3 months | 12 months
Get New Amicus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOLD

Average Price Target: $20.42
▲ +105.61% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Amicus Therapeutics in the last 3 months. The average price target is $20.42, with a high forecast of $31.00 and a low forecast of $13.00. The average price target represents a 105.61% upside from the last price of $9.93.

Hold

The current consensus among 13 investment analysts is to hold stock in Amicus Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021SVB LeerinkReiterated RatingHoldHigh
5/27/2021Needham & Company LLCInitiated CoverageHoldLow
5/20/2021UBS GroupInitiated CoverageBuy$16.00High
4/19/2021Cantor FitzgeraldUpgradeNeutral ➝ OverweightN/A
4/13/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$17.00 ➝ $17.00High
3/22/2021SVB LeerinkLower Price TargetMarket Perform$15.00 ➝ $13.00N/A
3/8/2021Stifel NicolausInitiated CoverageHold$13.00N/A
3/3/2021Robert W. BairdReiterated RatingBuyHigh
3/1/2021Stifel NicolausInitiated CoverageHold$13.00 ➝ $13.00High
2/12/2021CitigroupLower Price Target$27.00 ➝ $16.00Low
2/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00Low
2/12/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00Low
12/28/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00 ➝ $30.00N/A
12/14/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$24.00 ➝ $30.00High
12/10/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00Low
12/10/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$20.00 ➝ $27.00Medium
11/11/2020Berenberg BankInitiated CoverageBuy ➝ Hold$21.00High
11/6/2020Robert W. BairdBoost Price TargetOutperform$20.00 ➝ $25.00Medium
11/6/2020SVB LeerinkBoost Price TargetOutperform$19.00 ➝ $24.00Medium
10/19/2020CowenReiterated RatingBuy$31.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
8/11/2020HC WainwrightReiterated RatingBuy$20.00High
8/11/2020CitigroupBoost Price TargetBuy$15.00 ➝ $20.00High
6/16/2020HC WainwrightReiterated RatingBuy$20.00Low
6/16/2020BTIG ResearchInitiated CoverageBuy$19.00Low
6/8/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/19/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$19.00High
5/18/2020JPMorgan Chase & Co.Boost Price TargetOverweight$18.00 ➝ $21.00High
5/9/2020Chardan CapitalReiterated RatingHold$12.50High
3/5/2020Chardan CapitalReiterated RatingHold$12.50Medium
3/3/2020HC WainwrightReiterated RatingBuy$20.00Low
2/4/2020Cantor FitzgeraldReiterated RatingOverweight$19.00 ➝ $20.00High
1/9/2020Robert W. BairdReiterated RatingBuy$20.00High
1/9/2020HC WainwrightReiterated RatingBuy$20.00High
11/21/2019HC WainwrightReiterated RatingBuy$20.00Medium
11/12/2019HC WainwrightBoost Price TargetBuy$18.00 ➝ $20.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightMedium
10/14/2019HC WainwrightReiterated RatingBuy$18.00Low
10/10/2019CowenSet Price TargetBuy$31.00Low
8/1/2019CowenReiterated RatingBuy$31.00Low
8/1/2019HC WainwrightReiterated RatingBuy$18.00High
7/15/2019HC WainwrightSet Price TargetBuy$18.00High
7/2/2019HC WainwrightReiterated RatingBuy$18.00Medium
6/17/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
6/5/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $19.00Low
5/8/2019Cantor FitzgeraldSet Price TargetBuy$20.00Low
4/22/2019Robert W. BairdSet Price TargetBuy$20.00Low
4/5/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$13.91Medium
2/26/2019Cantor FitzgeraldReiterated RatingBuy$20.00Medium
2/5/2019Cantor FitzgeraldReiterated RatingBuy$20.00Medium
1/29/2019Cantor FitzgeraldInitiated CoverageOverweight$20.00Medium
1/16/2019CitigroupUpgradeNeutral ➝ Buy$12.59Medium
12/17/2018GuggenheimInitiated CoverageBuy$18.00High
10/29/2018CitigroupInitiated CoverageNeutral ➝ Neutral$12.00High
10/12/2018CowenReiterated RatingBuy$31.00Low
10/12/2018Chardan CapitalReiterated RatingHold$15.00High
8/17/2018Chardan CapitalDowngradeBuy ➝ Neutral$18.00 ➝ $15.00Medium
5/8/2018CowenReiterated RatingBuy$22.00Medium
2/8/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $24.00High
2/7/2018Robert W. BairdSet Price TargetBuy$20.00High
1/10/2018CowenReiterated RatingBuy$22.00Medium
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$17.00N/A
10/5/2017Chardan CapitalReiterated RatingBuy$16.50 ➝ $18.50N/A
10/4/2017Robert W. BairdReiterated RatingOutperform$16.00 ➝ $18.00N/A
10/4/2017JPMorgan Chase & Co.Reiterated RatingOverweightN/A
10/4/2017SVB LeerinkReiterated RatingBuy$17.00 ➝ $20.00Medium
10/4/2017Bank of AmericaBoost Price TargetBuy$15.00 ➝ $20.00High
9/25/2017Robert W. BairdReiterated RatingOutperform$16.00Low
9/16/2017SVB LeerinkReiterated RatingOutperform$18.00 ➝ $17.00Low
9/14/2017CowenReiterated RatingOutperform$16.00 ➝ $18.00Low
9/13/2017Chardan CapitalReiterated RatingBuy ➝ Buy$17.50 ➝ $16.50Low
8/14/2017CowenReiterated RatingBuy$16.00Low
8/10/2017Chardan CapitalBoost Price TargetBuy ➝ Buy$12.50 ➝ $17.50High
8/9/2017JPMorgan Chase & Co.Reiterated RatingOverweight$13.00 ➝ $15.00High
7/12/2017Robert W. BairdBoost Price TargetOutperform$12.00 ➝ $15.00Medium
7/11/2017CowenReiterated RatingBuy$10.00 ➝ $16.00Medium
6/30/2017Robert W. BairdReiterated RatingOutperform$12.00Low
6/5/2017JPMorgan Chase & Co.Set Price TargetBuy$13.00Low
6/1/2017Chardan CapitalReiterated RatingBuy$12.50Medium
5/25/2017Bank of AmericaLower Price TargetBuy$10.00 ➝ $9.00Medium
5/17/2017Robert W. BairdReiterated RatingOutperform$10.00 ➝ $12.00High
3/30/2017SVB LeerinkReiterated RatingOutperform$15.00Medium
1/31/2017Robert W. BairdUpgradeOutperformN/A
1/24/2017Robert W. BairdUpgradeNeutral ➝ Outperform$7.00 ➝ $10.00N/A
12/8/2016CowenSet Price TargetBuy$12.00N/A
11/30/2016SVB LeerinkReiterated RatingOutperform$17.00 ➝ $15.00N/A
11/30/2016CowenReiterated RatingOutperform$15.00 ➝ $12.00N/A
11/30/2016JPMorgan Chase & Co.Reiterated RatingOverweight$12.00 ➝ $11.00N/A
11/29/2016Robert W. BairdReiterated RatingHold$9.00 ➝ $7.00N/A
11/29/2016Chardan CapitalReiterated RatingBuy$15.00 ➝ $16.00N/A
11/8/2016SVB LeerinkReiterated RatingBuy$17.00N/A
11/8/2016CowenReiterated RatingOutperform$15.00N/A
8/11/2016Chardan CapitalSet Price TargetBuy$15.00N/A
(Data available from 6/20/2016 forward)
Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $9.93
Low: $9.68
High: $10.08

50 Day Range

MA: $9.72
Low: $8.71
High: $10.72

52 Week Range

Now: $9.93
Low: $8.68
High: $25.39

Volume

3,519,949 shs

Average Volume

3,436,860 shs

Market Capitalization

$2.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Amicus Therapeutics?

The following equities research analysts have issued reports on Amicus Therapeutics in the last twelve months: Berenberg Bank, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for FOLD.

What is the current price target for Amicus Therapeutics?

12 Wall Street analysts have set twelve-month price targets for Amicus Therapeutics in the last year. Their average twelve-month price target is $20.42, suggesting a possible upside of 105.6%. Cowen Inc has the highest price target set, predicting FOLD will reach $31.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $13.00 for Amicus Therapeutics in the next year.
View the latest price targets for FOLD.

What is the current consensus analyst rating for Amicus Therapeutics?

Amicus Therapeutics currently has 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FOLD, but not buy more shares or sell existing shares.
View the latest ratings for FOLD.

What other companies compete with Amicus Therapeutics?

How do I contact Amicus Therapeutics' investor relations team?

Amicus Therapeutics' physical mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company's listed phone number is 609-662-2000 and its investor relations email address is [email protected] The official website for Amicus Therapeutics is www.amicusrx.com.